Parexel’s patient advocacy group

Parexel shared a post on LinkedIn:
Parexel recently hosted its inaugural Patient Advocacy Group Forum, focusing on how socioeconomic status impacts clinical trial participation. We delved into insights from a Parexel-sponsored survey of 4,000+ patients to better understand barriers to access and foster inclusivity.

Our forum brought together attendees from all over the globe, representing diverse therapeutic areas. Watch below to learn how Parexel’s Patient Advocacy Group Forums are working to transform the clinical trial landscape through patient insights.”

Stacy Hurt, reposted Parexel’s post on LinkedIn, adding:

“Our top priority is to include a patient voice on every proposal for clinical trial design. A patient with lived experience should have input into protocol development for clinical trial delivery. We partner closely with our pharma/biotech sponsors to ensure this happens.

This is how we operationalize our core value of being patients first.”

Source: Parexel/LinkedIn  and Stacy Hurt/LinkedIn

Stacy Hurt is a Global Annual Meeting Program Committee member for Drug Information Association (DIA) and co-chair of the board for the American Cancer Society Northeast Region (Pittsburgh market). Stacy’s impact earned her a spot on Fierce Pharma’s 2023 Fierce 50 list as a Patient Advocacy Honoree.